Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS
NCT05795140Phase 3Recruiting
- Lead sponsor
- Novartis Pharmaceuticals (Industry)
- Enrollment
- 65 (estimated)
- Start date
- 8 May 2024
- Primary completion
- 16 Jul 2032 (estimated)
- Study completion
- 27 Jul 2032
- Last update posted
- 4 Jun 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None
- Arms
- 1
Interventions
- Iptcaopan 200 mg Drug
Conditions and primary outcome
- Atypical Hemolytic Uremic Syndrome
Primary outcome
Number of participants with adverse events and serious adverse events (Throughout the study duration, up to 4 years)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT05795140.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT05795140 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.